抑肝散加人参陈皮半夏颗粒治疗自闭症谱系障碍儿童的安全性、有效性及经济学评价:一项前瞻性、多中心、随机、双盲、安慰剂对照、平行组临床试验的研究方案
BACKGROUND: Autism spectrum disorder (ASD) is characterized by continuous impairment in communication and social interaction and by limited and repetitive behaviors, interests, or activities.…
要点
- 纳入4至6岁自闭症谱系障碍儿童,随机分为UGSJB颗粒联合针刺组与安慰剂联合针刺组,每组120例。
- 主要结局包括儿童自闭症评定量表、自闭症行为量表、异常行为量表、社会成熟度量表、儿童健康问卷、EuroQoL五维五水平青少年版及父母压力指数。
- 将在基线及治疗开始后6、12、24周进行评估,并调查UGSJB颗粒可能引起的不良反应及进行经济学评价。
核心结论
- 本研究旨在比较UGSJB联合针刺与安慰剂联合针刺对自闭症谱系障碍儿童症状的安全性和有效性,结果将为UGSJB联合针刺的安全性、有效性和经济价值提供临床证据。
研究设计与样本
- 前瞻性、多中心、随机、双盲、安慰剂对照、平行组临床试验。
- 计划纳入4至6岁自闭症谱系障碍儿童,随机分为UGSJB颗粒联合针刺组(n=120)和安慰剂联合针刺组(n=120),每日两次。
- 在基线及治疗开始后6、12、24周进行评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autism spectrum disorder (ASD) is characterized by continuous impairment in communication and social interaction and by limited and repetitive behaviors, interests, or activities. Behavioral, educational, and pharmaceutical interventions have been shown to reduce behavioral disabilities, improve verbal/non-verbal communication, and help patients acquire self-reliance skills. However, there has been a lack of systematic verification and consensus regarding the treatment of the core symptoms of ASD because of its unclear etiology. Ukgansangajinpibanha (UGSJB), a legitimately prescribed herbal medicine for nervousness, insomnia, night crying, and malnutrition in South Korea and Japan, has been used for angry, sensitive, nervous, and unsettled children with ASD. METHODS/DESIGN: This trial is a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, clinical trial. The 4- to 6-year-old children with ASD will be randomly assigned to following groups: 1. A UGSJB granule with acupuncture, twice daily (n = 120) 2. A placebo group with acupuncture, twice daily (n = 120). The following outcome measures will be used: behavior by the Childhood Autism Rating Scale, Autism Behavior Checklist, and Aberrant Behavior Checklist; social maturity by the Social Maturity Scale; quality of life by the Child Health Questionnaire and EuroQoL Five-dimension Five-level Youth; and parental stress by the Parenting Stress Index at baseline and at 6, 12, and 24 weeks after the beginning of treatment. In addition, to evaluate safety, we will investigate the adverse reactions that may be caused by UGSJB granule. Finally, we will make an economic evaluation of UGSJB for the treatment of ASD. DISCUSSION: We prepared a well-designed clinical trial to investigate the safety and effectiveness of UGSJB on ASD symptoms compared with placebo treatment. The results from this study will provide clinical evidence on the safety, effectiveness, and economic value of UGSJB combined with acupuncture in children with ASD. TRIAL REGISTRATION: Clinical Research Information Service: KCT0003007 (registered on April 5, 2018).
引用
- Lee SH, Shin S, Kim TH, et al. Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial. Trials. 2019. PMID: 31307524. doi:10.1186/s13063-019-3537-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。